Please try another search
For the six months ended 30 June 2009, ReGenBiologics, Inc. revenues increased 22% to $706K. Net lossapplicable to common stockholders increased from $4.7M to$9.6M. Revenues reflect Sales increase of 24% to $689K.Higher net loss reflects Interest Expense increase from$188K to $1.4M (expense), Research/Development increase of43% to $2.9M (expense), Interest Income decrease of 73% to$12K (income).
Period Ending: | Jun 30, 2009 | Mar 31, 2009 | Dec 31, 2008 | Sep 30, 2008 |
---|---|---|---|---|
Total Revenue | 0.41 | 0.3 | 0.41 | 0.38 |
Gross Profit | 0.23 | 0.16 | 0.22 | 0.17 |
Operating Income | -4.07 | -4.12 | -2.56 | -2.09 |
Net Income | -4.16 | -5.37 | -2.95 | -2.37 |
Period Ending: | Jun 30, 2009 | Mar 31, 2009 | Dec 31, 2008 | Sep 30, 2008 |
---|---|---|---|---|
Total Assets | 4.65 | 7.95 | 2.29 | 2.97 |
Total Liabilities | 10.66 | 10.64 | 12.2 | 11.19 |
Total Equity | -6.02 | -2.69 | -9.91 | -8.21 |
Period Ending: | Jun 30, 2009 | Mar 31, 2009 | Dec 31, 2008 | Sep 30, 2008 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -6.43 | -2.79 | -6.78 | -5.12 |
Cash From Investing Activities | -0.06 | -0.04 | 0.07 | 0.08 |
Cash From Financing Activities | 8.71 | 8.71 | 2.89 | 2.44 |
Net Change in Cash | 2.22 | 5.87 | -3.76 | -2.55 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review